. 2022 Oct 10;43(3):1027–1062. doi: 10.1007/s10792-022-02480-6

Table 1.

Observational studies comparing refractive errors and biometric measurements between IVB, IVR, diode LPC treatment modalities for TR-ROP

Authors/first author	Year	Participants	Treatment modalities being compared	Outcomes	Risk-of-bias assessment with ROBINS-I tool⁹
Kang et al. [10]	2019	30 eyes (diode LPC group) 20 eyes (IVB group) 2 eyes (IVR group)	IVB (0.625 mg/0.025 mL), IVR (0.2 mg/0.02 mL), Diode LPC	No differences between groups at age of 4 years in: Mean spherical power (P = 0.490, ANOVA test), Mean cylinder power (P = 0.290, ANOVA test), Mean spherical equivalence (P = 0.600, ANOVA test)	Moderate overall risk of bias
Kabatas et al. [11]	2017	24 eyes of 12 type 1 ROP infants (IVB group), 12 eyes of 6 type 1 ROP infants (IVR group), 72 eyes of 36 type 1 ROP infants (diode LPC group)	IVB (0.625 mg/0.025 mL, 100 mg/ 4 ml flacon) with diode LPC, IVR (0.25 mg/0.025 mL, 10 mg/1 ml flacon) with diode LPC, IVB (0.625 mg/0.025 mL, 100 mg/4 ml flacon) with IVR (0.25 mg/0.025 mL, 10 mg/1 ml flacon)	No differences between groups in Mean spherical equivalent at 18 months CA (P = 1.000, P = 1.000, P = 1.000 respectively), Mean cylindrical value at 18 months CA (P = 0.456, P = 1.000, P = 1.000 respectively)	Serious overall risk of bias due to baseline and time-varying confounding
Gunay et al. [12]	2017	55 infants with TR-ROP (IVB group) 22 infants with TR-ROP (IVR group) 57 infants with TR-ROP (diode LPC group)	IVB (0.625 mg/0.025 mL), IVR (0.25 mg/0.025 mL), Diode LPC	No differences between groups in: Spherical equivalent at 1.5 years CA (P = 0.130, ANOVA test), Rate of myopia (SE ≤ − 0.25 D) at 1.5 years CA (P = 0.080, ANOVA test), Rate of high myopia (SE ≤ − 5.0 D) at 1.5 years CA (P = 0.970, ANOVA test) Mean AL at 1.5 years CA (P = 0.390, ANOVA test)	Critical overall risk of bias due to baseline and time-varying confounding

Authors/first author

Year

Participants

Treatment modalities being compared

Outcomes

Risk-of-bias assessment with ROBINS-I tool⁹

Kang et al. [10]

2019

30 eyes (diode LPC group)

20 eyes (IVB group)

2 eyes (IVR group)

IVB (0.625 mg/0.025 mL),

IVR (0.2 mg/0.02 mL),

Diode LPC

No differences between groups at age of 4 years in:

Mean spherical power (P = 0.490, ANOVA test),

Mean cylinder power (P = 0.290, ANOVA test),

Mean spherical equivalence (P = 0.600, ANOVA test)

Moderate overall risk of bias

Kabatas et al. [11]

2017

24 eyes of 12 type 1 ROP infants (IVB group),

12 eyes of 6 type 1 ROP infants (IVR group),

72 eyes of 36 type 1 ROP infants (diode LPC group)

IVB (0.625 mg/0.025 mL, 100 mg/ 4 ml flacon) with diode LPC,

IVR (0.25 mg/0.025 mL, 10 mg/1 ml flacon) with diode LPC, IVB (0.625 mg/0.025 mL, 100 mg/4 ml flacon) with IVR (0.25 mg/0.025 mL, 10 mg/1 ml flacon)

No differences between groups in

Mean spherical equivalent at 18 months CA (P = 1.000, P = 1.000, P = 1.000 respectively),

Mean cylindrical value at 18 months CA (P = 0.456, P = 1.000, P = 1.000 respectively)

Serious overall risk of bias due to baseline and time-varying confounding

Gunay et al. [12]

2017

55 infants with TR-ROP (IVB group)

22 infants with TR-ROP (IVR group)

57 infants with TR-ROP (diode LPC group)

IVB (0.625 mg/0.025 mL),

IVR (0.25 mg/0.025 mL),

Diode LPC

No differences between groups in:

Spherical equivalent at 1.5 years CA (P = 0.130, ANOVA test),

Rate of myopia (SE ≤ − 0.25 D) at 1.5 years CA (P = 0.080, ANOVA test),

Rate of high myopia (SE ≤ − 5.0 D) at 1.5 years CA (P = 0.970, ANOVA test)

Mean AL at 1.5 years CA (P = 0.390, ANOVA test)

Critical overall risk of bias due to baseline and time-varying confounding

IVB intravitreal bevacizumab, IVR intravitreal ranibizumab, LPC laser photocoagulation, TR-ROP treatment-requiring retinopathy of prematurity, ROBINS-I risk of bias in non-randomized studies of interventions, ROP retinopathy of prematurity, ANOVA analysis of variance, SE spherical equivalent, D diopter(s), CA corrected age, AL axial length (mm)